Abstract: The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method for producing the coenzyme-binding glucose dehydrogenase, and a method and a reagent for measuring employing the coenzyme-binding glucose dehydrogenase. According to the invention, the coenzyme-binding glucose dehydrogenase can be applied to an industrial field, and a use becomes possible also in a material production or analysis including a method for measuring or eliminating glucose in a sample using the coenzyme-binding glucose dehydrogenase as well as a method for producing an organic compound. It became also possible to provide a glucose sensor capable of accurately measuring a blood sugar level.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
April 27, 2021
Assignees:
Ikeda Food Research Co., Ltd., PHC Corporation
Abstract: The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations.
Type:
Grant
Filed:
January 26, 2017
Date of Patent:
March 23, 2021
Assignees:
THE TEXAS A&M UNIVERSITY SYSTEM, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Allison R. Ficht, Kenneth Carson, Cynthia Sheffield, John Herbert Waite
Abstract: The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of
Abstract: The present disclosure relates to the use of a switch for the production of heterologous non-catabolic compounds in microbial host cells. In one aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured under aerobic conditions followed by microaerobic conditions, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions. In another aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured in the presence of maltose followed by the reduction or absence of maltose, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions.
Abstract: Methods for enzyme-enhanced CO2 capture include contacting a CO2-containing gas with an aqueous absorption solution at process conditions—such as high temperature, high pH, and/or using carbonate-based solutions—in the presence of Thermovibrio ammonificans carbonic anhydrase (TACA) or functional derivative thereof for catalyzing the hydration reaction of CO2 into bicarbonate and hydrogen ions and/or catalyzing the desorption reaction to produce a CO2 gas. The TACA may be provided to flow with the solution to cycle through a CO2 capture system that includes an absorber and a stripper.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
February 23, 2021
Assignee:
SAIPEM S.P.A.
Inventors:
Normand Voyer, Richard Daigle, Éric Madore, Sylvie Fradette
Abstract: The present disclosure relates to recombinant microorganisms engineered for enhance production of a desired amino acid, as well as related biomass, and compositions which are useful, inter alia, as animal feed ingredients. The present invention also provides related methods.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
January 12, 2021
Assignee:
CALYSTA, INC.
Inventors:
Renee M. Saville, Joshua A. Silverman, Eric G. Luning, Brandon D. Doss, Lorraine Joan Giver, Sol M. Resnick, Drew D. Regitsky
Abstract: Disclosed herein is a method of producing collagen particles. Each of the collagen particle is characterized in having a particle size of about 10-250 ?m, in which the integrity of collagen fibers therein is relatively intact.
Type:
Grant
Filed:
August 11, 2016
Date of Patent:
January 5, 2021
Assignee:
ACRO BIOMEDICAL COMPANY. LTD.
Inventors:
Jun-Jie Wang, Pei-Hua Tsai, Kai-Chi Ku, Dar-Jen Hsieh
Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
December 15, 2020
Assignee:
Halozyme, Inc.
Inventors:
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
Type:
Grant
Filed:
March 8, 2017
Date of Patent:
November 10, 2020
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
November 10, 2020
Assignee:
Synthetic Biologics, Inc.
Inventors:
Andrew Bristol, Michael Kaleko, Sheila Connelly
Abstract: The invention provides non-naturally occurring microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing carbon flux through acetyl-CoA. In some embodiments, the microbial organisms having such pathways also include pathways for generating reducing equivalents, formaldehyde fixation and/or formate assimilation. The enhanced carbon flux through acetyl-CoA, in combination with pathways for generating reducing equivalents, formaldehyde fixation and/or formate assimilation can, in some embodiments, be used for production of a bioderived compound. Accordingly, in some embodiments, the microbial organisms of the invention can include a pathway capable of producing a bioderived compound of the invention.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
October 20, 2020
Assignee:
Genomatica, Inc.
Inventors:
Robin E. Osterhout, Anthony P. Burgard, Priti Pharkya, Stefan Andrae
Abstract: The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
October 6, 2020
Assignee:
Genomatica, Inc.
Inventors:
Robin E. Osterhout, Anthony P. Burgard, Priti Pharkya, Mark J. Burk
Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.
Type:
Grant
Filed:
April 13, 2018
Date of Patent:
September 29, 2020
Assignees:
JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventors:
Huilei Yu, Yan Zhang, Jianhe Xu, Qian Zhao, Jiang Pan, Feng Liu, Guoqiang Lin
Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
Abstract: The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.
Type:
Grant
Filed:
March 5, 2015
Date of Patent:
August 18, 2020
Assignees:
SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Joseph Noel, Kate Woods, Marianne Bowman, Gordon Louie, Nancy Anderson Da Silva, Javier Pascual Cardenas
Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
Type:
Grant
Filed:
October 24, 2018
Date of Patent:
August 18, 2020
Assignee:
The Regents of the University of California
Inventors:
Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Ruth Bertozzi